The SOLAR-1 phase III trial of alpelisib plus fulvestrant in PIK3CA-mutated HR+ metastatic BC showed an improved PFS over fulvestrant monotherapy.7 However, despite this relevant clinical benefit, resistance remains a challenge. This evidence concerns the gene PIK3CA and breast cancer.